S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10

2 Downgrades In Healthcare You Might Want To Buy

Friday, October 8, 2021 | Thomas Hughes
2 Downgrades In Healthcare You Might Want To Buy

When Opportunity Knocks In The Healthcare Industry

Today we’re focusing on two stocks in the real of healthcare that just received some notable analyst activity. The activity is notable because it is bearish in light of recent market expectations and opens up what we see as potentially high-return entry opportunities. In both cases the analysts have reason to lower their targets or downgrade the stocks but also in both cases, the long-term opportunities are still present. If you’re looking for a place to park some money in the healthcare industry and can handle above-average risk Accolade and Allogene Therapeutics is well worth the look. 

No Applause For Accolade Results

Accolade (NASDAQ: ACCD) is a disruptor in the field of managed healthcare offering employers a way to provide their employees an end-to-end healthcare experience supported by the cloud. The company just reported earnings and, well, the bottom line results were far less than expected. The company reported a nearly 4X increase in operating expenses to outpace the 100% increase in revenue and post a loss nearly double the consensus expectations. The silver lining is that much of the money was reinvestment on business quality and growth that we see driving results in a later quarter. 

The bad news for current shareholders is that four Wall Street investment firms have come out in the wake of the release to lower their price targets. The silver lining here is that their consensus is still expecting roughly 30% of upside in the stock which is just a few hundred basis points below the broader consensus as reported by Marketbeat.com. Price action is down more than 4.0% in the wake of the target adjustments but still above what has been very strong support in the past. We expect to see support at the $37 level thoroughly tested but will be waiting for that support to confirm. If support confirms we see this stock begin bouncing back within days if not later in the session. 

Two Downgrades In Healthcare You Might Want To Buy

Allogene Therapeutics Clinical Trial Put On Hold 

Shares of Allogene Therapeutics (NASDAQ: ALLO) plummeted more than 35% in after-hours trading when the FDA put one of its clinical trials on hold. The trial is for a cancer treatment called AlloCAR T which caused a negative reaction in one of the test subjects. The FDA is reviewing the data and making comments at a later time. Until then, there have been at least seven major sell-siders to come out with commentary and only some of it is bearish. The general consensus is that this is a red flag for the company but may soon pass. The most bullish analysts see this as inconsequential in the long run and expect the study to resume at some later time. The therapy was given orphan drug status earlier this year because it had shown a positive risk/reward profile for the test group. 

So, of our seven fresh analyst call-outs, all seven lowered their price targets but only two downgraded the stock and there were even two upgrades. Roth Capital upgraded to Buy from Hold while RBC, which carries the highest of the newly-lowered price targets at $45, upgraded to Outperform from Hold. The broader Marketbeat.com consensus target is $37.75. As far as price action, shares of the stock are still down more than 35% and trading at the lowest level since the IPO.

Two Downgrades In Healthcare You Might Want To Buy

Should you invest $1,000 in Accolade right now?

Before you consider Accolade, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Accolade wasn't on the list.

While Accolade currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here


Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Accolade (ACCD)2.5$39.01-3.0%N/A-16.53Buy$56.20
Allogene Therapeutics (ALLO)2.4$15.82flatN/A-8.64Buy$36.23
Compare These Stocks  Add These Stocks to My Watchlist 


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.